The article reports on a 2013 decision which the European Union's Committee on Medicinal Products for Human Use made to recommend that the use of cilostazol-containing medicines used to treat intermittent claudication should be restricted.EBSCO_AspWho Drug Information...
Ticlopidine, which is a medicine used to prevent stroke Diltiazem, which is a medicine to treat chest pain and high blood pressure Omeprazole, which is a medicine to treat indigestion, heartburn, and acid reflux Saquinavir or ritonavir, which are medicines to treat HIV ...
Percutaneous coronary interventions (PCI) are widely used to treat patients with ischemic heart disease. But the high rate of late restenosis through intim... YD Chen,LU Yan-ling,JIN Ze-ning,... - 《中华医学杂志(英文版)》 被引量: 121发表: 2006年 Randomized Comparison of Cilostazol vs Clop...
Background: Cilostazol is a type III phosphodiesterase inhibitor used to treat the symptoms of intermittent claudication. Recent studies have shown that ci... Fujii, TakuObara, HideakiMatsubara, KentaroFujimura, NaokiYagi, HiroshiHibi, TaizoAbe, YutaKitago, MinoruShinoda, MasahiroItano, OsamuTanabe, ...
E-mail, kpark@knu.ac.kr Received 20 May 2013; revised 10 October 2013; accepted 21 October 2013 Cilostazol inhibits expression of SREBP-1c Y-A Jung et al 2 The phosphodiesterase V inhibitor cilostazol is an anti- platelet agent used to treat patients with diabetic vascular complications.9,...
. Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W TKO /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer ...
rhythmiageneration.wetestedtheeffectsofcilostazoloncardiacmitochondriaundersevereoxidativestress.Methods Mitochondriawere isolatedfromratheartsandtreatedwithH202toinduceoxidativestress.Cilostazol,atvariousconcentrations,wasusedtostudyitsprotective effects.Pharmacologicalinterventions,includingamitochondrialpermeabilitytransitionpore...
Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of intermittent claudication and increase walking distance in patients with peripheral arterial disease (PAD). At the time of approval, the United States Food and Drug Administration required an additional long-term safety...
RCTs were analyzed using an intention-to-treat analysis. Table I. Reported outcomes are subdivided into three major categories CategoryOutcome measureDefinition Limb-related outcomes Amputation-free survival (HR) Avoidance of major amputation (above knee, below knee). Minor amputation was considered to...
Cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H )-quinolinone) is used to treat symptoms of intermittent claudication in patients suffering from symptoms of the disease, which include pain and cramping while walking due to reduced blood flow to the legs. Cilostazol...